ANGPTL3 and hepatocellular carcinoma: Silencing of ANGPTL3 in mouse models and in human hepatoma cells result in reduced output and increased uptake of Apo B-containing lipoproteins (Xu et al., 2018), thereby contributing to low LDL-CHOL observed in mice and humans with genetic ANGPTL3 deficiency (Musunuru et al., 2010).